CCDC85B Activators
CCDC85B operate through various mechanisms to enhance the protein's activation, primarily by increasing intracellular cyclic AMP (cAMP) levels or mimicking its action, thus promoting the phosphorylation of CCDC85B by protein kinase A (PKA). Forskolin, for instance, directly stimulates adenylyl cyclase, the enzyme responsible for the synthesis of cAMP from ATP, leading to an upsurge in cAMP within the cell. This surge in cAMP activates PKA, which in turn phosphorylates CCDC85B, culminating in its activation. Similarly, Prostaglandin E1 (PGE1) activates adenylate cyclase, contributing to the same cascade that results in the activation of CCDC85B.
Several other chemicals inhibit phosphodiesterases, the enzymes tasked with cAMP degradation, which results in elevated levels of this secondary messenger. Isobutylmethylxanthine (IBMX), Rolipram, Cilostamide, Milrinone, Anagrelide, Vinpocetine, Zardaverine, Pentoxyfylline, and EHNA all function by this mechanism but differ in their specificity for various phosphodiesterase isoforms. By preventing the breakdown of cAMP, these inhibitors ensure sustained activation of PKA, which consistently phosphorylates CCDC85B. Alternatively, Sp-8-Br-cAMPS, being a cAMP analog, resists hydrolysis by phosphodiesterases and directly activates PKA, bypassing the need for upstream cAMP accumulation. The result is a robust activation of PKA, which then targets CCDC85B for phosphorylation and subsequent activation. Each of these chemical activators, through their distinct interactions with cellular components involved in cAMP signaling, ensures the activation of PKA and the phosphorylation of CCDC85B.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. By preventing cAMP degradation, IBMX indirectly increases PKA activity, which can phosphorylate and activate CCDC85B. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which specifically degrades cAMP in some cells. Inhibition of PDE4 leads to increased cAMP levels, potentially enhancing PKA-mediated activation of CCDC85B. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide selectively inhibits phosphodiesterase 3 (PDE3), leading to accumulation of cAMP in certain cell types. This rise in cAMP can activate PKA, which is capable of phosphorylating CCDC85B, thus activating it. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a PDE3 inhibitor that increases intracellular cAMP levels, leading to activation of PKA. PKA can then phosphorylate CCDC85B, leading to its activation. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide is another PDE3 inhibitor that elevates cAMP levels, and thereby, PKA activity can be increased. Active PKA has the capacity to phosphorylate CCDC85B, resulting in its activation. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor that can lead to increased cAMP levels, indirectly supporting the activation of PKA. PKA, in turn, can phosphorylate CCDC85B, leading to its activation. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 (PGE1) activates adenylate cyclase, which increases cAMP levels, thereby activating PKA. PKA can phosphorylate CCDC85B, resulting in activation of the protein. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a dual PDE3 and PDE4 inhibitor, which increases cAMP concentrations, enhancing PKA activation. PKA can then phosphorylate and activate CCDC85B. | ||||||
Pentoxifylline | 6493-05-6 | sc-203184 | 1 g | $20.00 | 3 | |
Pentoxyfylline is a non-selective phosphodiesterase inhibitor. By increasing cAMP levels, it indirectly promotes PKA activation, which can lead to the phosphorylation and activation of CCDC85B. | ||||||